8-K: NKGen Biotech Issues Shares to Kepos Alpha Master Fund in Warrant Exercise and Downside Protection Agreement

NKGen Biotech issues common stock to Kepos Alpha Master Fund to satisfy warrant exercises and downside protection obligations.

Summary

• NKGen Biotech entered into a letter agreement with Kepos Alpha Master Fund L.P. on April 25, 2025.
• Kepos exercised 555,555 warrants on a cashless basis, resulting in the issuance of 555,555 shares of NKGen's common stock.
• In lieu of a $509,555 cash payment for Additional Downside Consideration, NKGen issued 2,038,220 shares at $0.25 per share.
• NKGen issued a total of 2,593,775 shares to Kepos, including the Warrant Shares and Additional Shares.
• Kepos agreed to accept 1,528,888 shares in lieu of $382,222 in Downside Protection Cash from a prior exercise, with the share price calculated at $0.25.
• These shares are unregistered and subject to transfer restrictions.
• The agreement does not modify the original warrant terms except as explicitly stated.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the dilution of shares and the company's reliance on equity financing to meet its obligations, indicating potential financial strain.

Positives

• NKGen Biotech avoids immediate cash outlays by issuing shares in lieu of cash payments.
• The agreement satisfies Kepos's rights to Downside Protection for the Warrants as of the Third Reset Date.
• The company has resolved outstanding obligations related to warrant exercises and downside protection.

Negatives

• The issuance of a significant number of new shares could dilute existing shareholders' equity.
• The company is issuing shares at $0.25 per share to cover downside protection, which may indicate a lower perceived value of the stock.
• The reliance on share issuance to cover obligations may reflect cash flow challenges.

Risks

• The newly issued shares are unregistered and subject to transfer restrictions, potentially limiting their liquidity.
• If the stock price falls below $0.25 on the Determination Date, the company may need to provide additional consideration to Kepos.
• Continued reliance on equity financing could further dilute shareholder value.

Future Outlook

The company will issue additional shares to Kepos prior to filing its next S-1 registration statement to cover the outstanding Downside Protection Cash, potentially with additional consideration if the stock price is below $0.25 on the Determination Date.

Management Comments

• The letter agreement sets forth the terms and mutual acknowledgements regarding the conversion of certain warrants held by Kepos Alpha Master Fund L.P.

Industry Context

This type of agreement is common in situations where companies need financing but may not have sufficient cash reserves, often seen in smaller biotech firms. It allows them to continue operations by leveraging equity.

Comparison to Industry Standards

• Similar warrant and downside protection agreements are often seen with companies like Cassava Sciences (SAVA) and Ocugen (OCGN), which have used similar financing mechanisms.
• The $0.25 per share valuation for downside protection is relatively low, suggesting a higher risk profile compared to companies with stronger financial positions.
• Compared to larger biotech firms like Amgen (AMGN) or Gilead Sciences (GILD), NKGen's reliance on such agreements indicates a weaker financial standing.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• Kepos benefits from the conversion of warrants and downside protection into equity.
• The company's ability to fund operations is supported by this agreement, potentially benefiting employees and other stakeholders in the long term.

Next Steps

• The company will issue 1,528,888 shares of common stock to Kepos prior to the filing of the next S-1 registration statement.
• The company may need to provide additional consideration to Kepos if the stock price is below $0.25 on the Determination Date.

Key Dates

Keywords

NKGen Biotech, Kepos Alpha Master Fund, warrant exercise, downside protection, share issuance, common stock, dilution, financing